Pdt Partners, LLC C4 Therapeutics, Inc. Transaction History

Pdt Partners, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$2.75 - $3.77 $157,000 - $215,233	-57,091 Reduced 72.71%	21,432 $58,000
Q1 2023 May 15, 2023	BUY	$3.1 - $9.02 $65,568 - $190,782	21,151 Added 36.87%	78,523 $246,000
Q4 2022 Feb 14, 2023	BUY	$5.42 - $10.24 $85,012 - $160,614	15,685 Added 37.63%	57,372 $338,000
Q3 2022 Nov 14, 2022	SELL	$8.03 - $12.77 $532,999 - $847,621	-66,376 Reduced 61.42%	41,687 $366,000
Q2 2022 Aug 15, 2022	BUY	$5.06 - $26.46 $546,798 - $2.86 Million	108,063 New	108,063 $815,000

130

63.5M

670K

54.8K

Ticker CCCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,913,800
Market Cap $214M
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Pdt Partners, LLC with notifications on news.